PostEra and NeuroLucent Join Hands to Identify small-molecule therapeutics for Alzheimer's disease

PostEra and NeuroLucent Join Hands to Identify small-molecule therapeutics for Alzheimer's disease

NeuroLucent is developing novel small molecule compounds that normalize a crucial calcium channel that is dysregulated in Alzheimer's neurons and restore normal neuronal function in multiple preclinical Alzheimer's models.

FREMONT, CA: PostEra, a biotechnology company offering medicinal chemistry powered by machine learning, collaborated with NeuroLucent, a Chicago-based company focused on creating novel treatments for Alzheimer's disease and other dementias.

The failure of late-stage clinical trials to discover effective therapies for Alzheimer's disease has emphasized the inevitability of exploring novel therapeutic approaches. NeuroLucent is developing novel small molecule compounds that normalize a crucial calcium channel that is dysregulated in Alzheimer's neurons and restore normal neuronal function in multiple preclinical Alzheimer's models.

NeuroLucent has joined hands with PostEra to speed up its search for a therapeutic candidate. PostEra will leverage its machine learning technology to optimize NeuroLucent's lead compounds through a series of 'design-make-test' cycles that have previously been shown to accelerate medicinal chemistry campaigns. PostEra will also leverage its Manifold platform, which provides access to compounds through a worldwide network of suppiers and partner contract research organizations.

Commercial terms include an upfront payment to PostEra, with additional payments upon the achievement of certain milestones.

"We're excited about the potential of integrating PostEra's technology into the design of more potent compounds," said Bill Kohlbrenner, CEO of NeuroLucent. "We are intrigued by PostEra's machine learning algorithm since it doesn't require detailed structural information related to the drug target. We are looking forward to seeing what impact PostEra's AI solutions will have on our program."